PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

BioInvent receives Investigational New Drug approval for monoclonal antibody BI-1910

BI-1910 is now the second of the company’s anti-tumour necrosis factor receptor 2 programmes to enter clinical development.

Swedish clinical-stage biotech company BioInvent has announced that it has received Investigational New Drug (IND) approval for its monoclonal antibody, making it the second of its anti-tumour necrosis factor receptor 2 (TNFR2) programmes to enter clinical development.

BI-1910 is a differentiated agonist approach compared to BioInvent’s first-in-class anti-TNFR2 antibody BI-1808, which is currently in a phase 1/2a trial. Both programmes were chosen from a large family of binders generated through BioInvent’s F.I.R.S.T technology platform. A surrogate of BI-1910 was used in experimental models, allowing the company to research more deeply pharmacodynamic biomarkers.

BioInvent will conduct a phase 1/2a clinical trial across US and Europe for BI-1910, with exploratory cohorts planned in hepatocellular carcinoma (HCC) and non-small cell lung cancer (NSCLC). The drug will also be tested by itself and in combination with pembrolizumab.

Martin Welschof, CEO of BioInvent, stated: “I am very excited to be moving BI-1910 into clinical trials to explore the potential of this differentiated anti-TNFR2 approach. We have built up a strong understanding of the biology of TNFR2 and this means we can move forward with two different monoclonal antibodies against this promising target. BI-1910 becomes the fifth product in clinical development, in six different trials, reflecting the productivity of the BioInvent technology platform and its potential to radically intervene on the tumour microenvironment and significantly improve treatment for cancer patients.”

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026